GlassScriptPhysician profile
Raj K Katara
NPI 1376568279
$3,694.26
in general payments reported to CMS, 2019-2025
19 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $225 · 2021: $344 · 2022: $271 · 2023: $425 · 2024: $236 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $737.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $575.61 | 2019-2021 | |
| Abbvie INC. | $536.07 | 2023-2025 | |
| Sk Life Science, INC. | $307.13 | 2020-2024 | Xcopri |
| Axsome Therapeutics, INC. | $210.26 | 2025 | Symbravo, Sunosi |
| Emd Serono, INC. | $192.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.82 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $167.32 | 2023 | Rexulti |
| Lundbeck LLC | $124.80 | 2019 | |
| Eisai INC. | $124.74 | 2025 | |
| Genzyme Corporation | $102.31 | 2021 | |
| Acorda Therapeutics, INC | $100.02 | 2019 | |
| Acadia Pharmaceuticals INC | $97.44 | 2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $85.02 | 2021 | |
| Biogen, INC. | $81.39 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $33.49 | 2023 | Inspire |
| Supernus Pharmaceuticals, INC. | $14.68 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.14 | 2024 | |
| Sunovion Pharmaceuticals INC. | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Katara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.